Literature DB >> 36187305

Pseudoxanthoma elasticum resulting in acute coronary syndrome.

Hiroki Ono1, Akira Oshita1, Shinji Inaba2, Moeko Kawamata1, Yasuhisa Nakao2, Teruyoshi Uetani1, Jun Muto3, Takeshi Joko4, Hideo Kawakami1.   

Abstract

Pseudoxanthoma elasticum (PXE) is a rare hereditary disorder that causes elastic tissue degeneration in the skin, eyes, and cardiovascular system. Gastrointestinal bleeding and fundus hemorrhage are serious complications associated with PXE prognosis as well as cardiovascular involvement. This is a rare case of acute coronary syndrome in a PXE patient with high bleeding risk. Learning objective: Pseudoxanthoma elasticum (PXE) resulting in acute coronary syndrome (ACS) is rare. Given PXE patients are generally at very high bleeding risk, antithrombotic therapy as secondary prevention after ACS onset should be taken into full consideration.
© 2022 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved. All rights reserved.

Entities:  

Keywords:  Acute coronary syndrome; Antithrombotic therapy; Pseudoxanthoma elasticum

Year:  2022        PMID: 36187305      PMCID: PMC9508624          DOI: 10.1016/j.jccase.2022.06.004

Source DB:  PubMed          Journal:  J Cardiol Cases        ISSN: 1878-5409


  8 in total

1.  Pseudoxanthoma elasticum diagnosed 25 years after the onset of cardiovascular disease.

Authors:  Y Araki; T Yokoyama; N Sagawa; S Okuno; Y Hoshino; Y Sando; A Hasegawa; M Kurabayashi
Journal:  Intern Med       Date:  2001-11       Impact factor: 1.271

Review 2.  Drug-Coated Balloons for Coronary Artery Disease: Third Report of the International DCB Consensus Group.

Authors:  Raban V Jeger; Simon Eccleshall; Wan Azman Wan Ahmad; Junbo Ge; Tudor C Poerner; Eun-Seok Shin; Fernando Alfonso; Azeem Latib; Paul J Ong; Tuomas T Rissanen; Jorge Saucedo; Bruno Scheller; Franz X Kleber
Journal:  JACC Cardiovasc Interv       Date:  2020-05-27       Impact factor: 11.195

3.  JCS 2020 Guideline Focused Update on Antithrombotic Therapy in Patients With Coronary Artery Disease.

Authors:  Masato Nakamura; Kazuo Kimura; Takeshi Kimura; Masaharu Ishihara; Fumiyuki Otsuka; Ken Kozuma; Masami Kosuge; Toshiro Shinke; Yoshihisa Nakagawa; Masahiro Natsuaki; Satoshi Yasuda; Takashi Akasaka; Shun Kohsaka; Kazuo Haze; Atsushi Hirayama
Journal:  Circ J       Date:  2020-03-13       Impact factor: 2.993

4.  Drug-coated balloon for treatment of de-novo coronary artery lesions in patients with high bleeding risk (DEBUT): a single-blind, randomised, non-inferiority trial.

Authors:  Tuomas T Rissanen; Sanna Uskela; Jaakko Eränen; Pirjo Mäntylä; Annika Olli; Hannu Romppanen; Antti Siljander; Mikko Pietilä; Mikko J Minkkinen; Jerry Tervo; Jussi M Kärkkäinen
Journal:  Lancet       Date:  2019-06-13       Impact factor: 79.321

5.  Characterization of cardiovascular involvement in pseudoxanthoma elasticum families.

Authors:  Laurence Campens; Olivier M Vanakker; Bram Trachet; Patrick Segers; Bart P Leroy; Julie De Zaeytijd; Dirk Voet; Anne De Paepe; Tine De Backer; Julie De Backer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-08-22       Impact factor: 8.311

6.  In-Hospital Bleeding and Utility of a Maintenance Dose of Prasugrel 2.5 mg in High Bleeding Risk Patients With Acute Coronary Syndrome.

Authors:  Masanobu Ohya; Takenobu Shimada; Kohei Osakada; Akimune Kuwayama; Katsuya Miura; Ryosuke Murai; Hidewo Amano; Shunsuke Kubo; Suguru Otsuru; Seiji Habara; Takeshi Tada; Hiroyuki Tanaka; Yasushi Fuku; Harumi Katoh; Tsuyoshi Goto; Kazushige Kadota
Journal:  Circ J       Date:  2018-04-26       Impact factor: 2.993

7.  Efficacy of 2.5-mg Prasugrel in Elderly or Low-Body-Weight Patients.

Authors:  Shinichi Wakabayashi; Noritaka Ariyoshi; Hideki Kitahara; Kenichi Fujii; Yoshihide Fujimoto; Yoshio Kobayashi
Journal:  Circ J       Date:  2018-06-29       Impact factor: 2.993

Review 8.  Pseudoxanthoma elasticum.

Authors:  Dominique P Germain
Journal:  Orphanet J Rare Dis       Date:  2017-05-10       Impact factor: 4.123

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.